A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130

Investigational New Drugs

Volumn 23, Issue 5, 2005, Pages 445-453

  Gelmon, Karen A ^a   Belanger, Karl ^b   Soulieres, Denis ^b   Britten, Carolyn ^a   Chia, Stephen ^a   Charpentier, Danielle ^b   Chi, Kim ^a   Powers, Jean ^c   Walsh, Wendy ^c   Seymour, Lesley ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Queen's Cancer Research Institute   (Canada)

Author keywords

Phase I; Tubulin active agent

Indexed keywords

ANTINEOPLASTIC AGENT; MITOMYCIN C; T 900607; TROPONIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE PAIN; BRADYCARDIA; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG POTENCY; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HALF LIFE TIME; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HICCUP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSALIVATION; INFECTION; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PERCEPTION DEAFNESS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SOLID TUMOR; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; URINE RETENTION; VOMITING; WOUND INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FATIGUE; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; SULFONAMIDES; THROMBOCYTOPENIA; VOMITING;

EID: 23844483703     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-2904-2     Document Type: Article

References (15)

1. Dumont C, Sikic BI: Mechanism of alteration of and resistance to antitubulin agents; microtubules dynamics, drug transport and cell death. J Clin Oncol 17: 1061-1078, 1999
2. Drukman S, Kavallaris M: Microtubule alteration and resistance to tubulin binding agents (Review). Int Jour of Oncol 21: 621-628, 2002
3. Teng M, Bartholomew J, Bissel M: Synergism between antimicrotubule agents and growth stimulants in enhancement of cell cycle traverse. Nature 268: 739-41, 1977
4. Jordan MA: Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Current Med Chem-Anticancer Agents 21: 1-17, 2002
5. Lewis SA, Cowen MJ: Tubulin genes, structure, expression and regulators of microtubule proteins. In: Avila J. (ed), CRC Press Inc. TL pp. 37-66, 1999
6. Kavallaris M, Kuo DY-S, Burkart CA, Regl DL, Norris MD, Haber M, Horowitz SB: Taxol resistant epithelial ovarian tumors are associated with altered expression of specific β tubulin isotypes. J Clin Inves 100: 1282-1293, 1999
7. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistant proteins. J Natl Cancer Inst 92: 1295-1302, 2000
8. Investigators Manual for T900607. Tularik Inc. 2000
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein C, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-16, 2000
10. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go As, Hlatky MA: The Prognostic Value of troponin in patients with non ST elevation acute coronary syndromes; a meta-analysis. Jour of Am Col of Cardio 38: 478-185, 2001
11. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Roberson DH, Hille DA, Delucca PT, DiBattisti PM, Demopoulos LA, Weintraub WS, Braunwald E: Ability of minor elevations of troponins I and T to predict benefit for an early invasive strategy in patients with unstable angina and non ST elevation myocardial infarctions; results from randomized trials. JAMA 286: 2405-2412, 2001
12. Antman EM, Tranasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E: Cardiac specific troponin I levels predict the risk of mortality in patients with acute coronary syndromes. NEJM 335: 1342-1349, 1996.
13. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr: National academy of clinical biochemistry standards of laboratory practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 45: 1104-1121, 1999
14. Antman EM: Decision Makers with Cardiac Troponin Tests. NEJM 346: 2079-2082, 2002
15. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E: Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.) Cirulation 109(5): 565-570, 2004